Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.

Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis / Moccia, Marcello; Loperto, Ilaria; Santoni, Laura; Masera, Silvia; Affinito, Giuseppina; Carotenuto, Antonio; Lanzillo, Roberta; Triassi, Maria; Morra, Vincenzo Brescia; Palladino, Raffaele. - In: NEURODEGENERATIVE DISEASE MANAGEMENT. - ISSN 1758-2024. - 12:3(2022), pp. 109-116. [10.2217/nmt-2021-0038]

Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis

Moccia, Marcello;Loperto, Ilaria;Affinito, Giuseppina;Carotenuto, Antonio;Lanzillo, Roberta;Triassi, Maria;Morra, Vincenzo Brescia;Palladino, Raffaele
2022

Abstract

Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.
2022
Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis / Moccia, Marcello; Loperto, Ilaria; Santoni, Laura; Masera, Silvia; Affinito, Giuseppina; Carotenuto, Antonio; Lanzillo, Roberta; Triassi, Maria; Morra, Vincenzo Brescia; Palladino, Raffaele. - In: NEURODEGENERATIVE DISEASE MANAGEMENT. - ISSN 1758-2024. - 12:3(2022), pp. 109-116. [10.2217/nmt-2021-0038]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/891490
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact